Worth reading
80Important
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
330
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFirst quarter of the fiscal year ending June 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,695 million+24.2%
Operating profit¥278 million+16.5%
Ordinary income¥283 million+16.3%
Net income¥191 million+15.8%
Operating profit margin16.4 %
Results for the three months of the current quarter
Net Sales
¥1,695 million
Operating profit
¥278 million
Ordinary income
¥283 million
Profit attributable to owners of parent for the quarter
¥191 million
EBITDA
¥382 million
Full-year earnings forecast
Net Sales
¥7,535 million
Operating profit
¥1,569 million
Ordinary income
¥1,569 million
Profit attributable to owners of the parent
¥1,005 million
EBITDA
¥1,954 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales22.5%
Operating profit17.7%
Ordinary income18.0%
Profit attributable to owners of the parent19.0%
EBITDA19.5%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progress above plan (consolidated total, animal hospital network business and contract research and development business) / progress in line with plan (medical and hygiene equipment business, biomaterials business and medical data solutions business)Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Revenue growth¥330 million
- Personnel expenses¥-130 million
- Procurement¥-44 million
- Goodwill amortization¥-13 million
- Other¥-104 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- AssumptionRevenue and operating income in the animal hospital network business are weighted toward the fourth quarter.
- AssumptionThe third quarter is the peak season for the medical and hygiene equipment business.
New initiatives
- Building a veterinary healthcare value-creation platform through strategic M&A
- Launch of sales of Photo Barrier405
- Planned launch of the Craft model disinfecting and deodorizing machine
- Proof-of-concept research on technology to inactivate avian influenza viruses
- Launch of manufacturing and sales of chitin nanofiber products and raw materials
- Joint research and AI implementation and development with ダイナコム on a veterinary healthcare database
- Strengthening the CRO and SMO businesses by making Meditrix a subsidiary
- Invitation of Dr. Ichikawa Yasuaki (市川康明) to serve as co-head of the Institute of Advanced Veterinary Medicine
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA¥382 millionYear on year against the same period last year+16.6%
- Earnings per share¥25.3Year on year against the same period last year+14.3%
- Equity ratio59.9 %Year on year against the same period last year+5.2 percentage points versus the end of the previous fiscal year
- Operating margin16.4 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Number of medical cases
12.5 thousand transactions
Average medical service price
¥448 thousand
Segment results
- Veterinary Hospital Network BusinessNet Sales¥1,479 millionOperating profit¥335 millionvs. Q1 forecastRevenue 101.2%, operating income 107.0%
- Medical and Hygiene Equipment BusinessNet Sales¥98 millionOperating profit¥-3 millionvs. Q1 forecastRevenue 102.1%; operating income of negative ¥3 million versus the forecast of negative ¥4 million
- Biomaterials BusinessNet Sales¥6 millionOperating profit¥1 millionvs. Q1 forecastRevenue 113.3%, operating income 121.8%
- Medical Data Solutions BusinessNet Sales¥31 millionOperating profit¥5 millionvs. Q1 forecastRevenue 102.2%, operating income 100.8%
- Contract Research and Development BusinessNet Sales¥81 millionOperating profit¥15 millionvs. Q1 forecastRevenue 108.3%, operating income 108.4%
Number of stores and locations
Number at period-end40 hospitals (as of 30 September 2026: 12 hub hospitals and 28 satellite hospitals)
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending June 2027 |
| Net Sales | ¥1,695 million (YoY +24.2%) |
| Operating profit | ¥278 million (YoY +16.5%) |
| Ordinary income | ¥283 million (YoY +16.3%) |
| Net income | ¥191 million (YoY +15.8%) |
| Operating profit margin | 16.4 % |
| Results for the three months of the current quarter | Net Sales ¥1,695 million / Operating profit ¥278 million / Ordinary income ¥283 million / Profit attributable to owners of parent for the quarter ¥191 million / EBITDA ¥382 million |
| Full-year earnings forecast | Net Sales ¥7,535 million / Operating profit ¥1,569 million / Ordinary income ¥1,569 million / Profit attributable to owners of the parent ¥1,005 million / EBITDA ¥1,954 million |
| Progress against full-year forecast | Net Sales 22.5% / Operating profit 17.7% / Ordinary income 18.0% / Profit attributable to owners of the parent 19.0% / EBITDA 19.5% |
| Self-assessment against the plan | Progress above plan (consolidated total, animal hospital network business and contract research and development business) / progress in line with plan (medical and hygiene equipment business, biomaterials business and medical data solutions business) |
| Segment results | Segment Veterinary Hospital Network Business / Net Sales ¥1,479 million / Operating profit ¥335 million / vs. Q1 forecast Revenue 101.2%, operating income 107.0%, Segment Medical and Hygiene Equipment Business / Net Sales ¥98 million / Operating profit ¥-3 million / vs. Q1 forecast Revenue 102.1%; operating income of negative ¥3 million versus the forecast of negative ¥4 million, Segment Biomaterials Business / Net Sales ¥6 million / Operating profit ¥1 million / vs. Q1 forecast Revenue 113.3%, operating income 121.8%, Segment Medical Data Solutions Business / Net Sales ¥31 million / Operating profit ¥5 million / vs. Q1 forecast Revenue 102.2%, operating income 100.8%, Segment Contract Research and Development Business / Net Sales ¥81 million / Operating profit ¥15 million / vs. Q1 forecast Revenue 108.3%, operating income 108.4% |
| Breakdown of Factors Affecting the Change | Factors Revenue growth / Amount ¥330 million, Factors Personnel expenses / Amount ¥-130 million, Factors Procurement / Amount ¥-44 million, Factors Goodwill amortization / Amount ¥-13 million, Factors Other / Amount ¥-104 million |
| Key KPIs | Indicator name EBITDA / Value ¥382 million / Year on year against the same period last year ¥16.6 million, Indicator name Earnings per share / Value ¥25.3 / Year on year against the same period last year ¥14.3, Indicator name Equity ratio / Value 59.9 % / Year on year against the same period last year +5.2 percentage points versus the end of the previous fiscal year, Indicator name Operating margin / Value 16.4 % / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Number of medical cases 12.5 thousand transactions / Average medical service price ¥448 thousand |
| Number of stores and locations | Number at period-end 40 hospitals (as of 30 September 2026: 12 hub hospitals and 28 satellite hospitals) / Number of store openings and closures during the period Not disclosed |
| Assumptions Underlying the Business Outlook | Assumption Revenue and operating income in the animal hospital network business are weighted toward the fourth quarter. / Figures Not disclosed, Assumption The third quarter is the peak season for the medical and hygiene equipment business. / Figures Not disclosed |
| New initiatives | Building a veterinary healthcare value-creation platform through strategic M&A, Launch of sales of Photo Barrier405, Planned launch of the Craft model disinfecting and deodorizing machine, Proof-of-concept research on technology to inactivate avian influenza viruses, Launch of manufacturing and sales of chitin nanofiber products and raw materials, Joint research and AI implementation and development with ダイナコム on a veterinary healthcare database, Strengthening the CRO and SMO businesses by making Meditrix a subsidiary, Invitation of Dr. Ichikawa Yasuaki (市川康明) to serve as co-head of the Institute of Advanced Veterinary Medicine |
Items this document does not state (13)
Gross Profit MarginSelling, general and administrative expensesNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to organic growth at existing hospitals and the effects of the acquisitions of Asuka Medical, See, Cartech, Meditrix and North One. Although amortization of goodwill and personnel expenses increased in connection with the M&A, operating income increased due to the effects of greater operating efficiency through group management, cost synergies and the expansion of medical equipment.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.